Physicochemical properties and antioxidant activity of gamma-oryzanol-loaded liposome formulations for topical use.
The objective of this study is to prepare the gamma-oryzanol-loaded liposomes and investigate their physicochemical properties and antioxidant activity intended for cosmetic applications. Liposomes, Composing phosphatidylCholine (PC) and Cholesterol (Chol), CHAPS or sodium taurocholate (NaTC) were prepared by sonication method. Gamma-oryzanol-loaded liposomes were prepared by using 3, 5 and 10% gamma-oryzanol as an initial concentration. The formulation factors in a particular type and composition of lipid and initial drug loading on the physicochemical properties (i.e., particle size, zeta potential, entrapment efficiency, drug release) and antioxidant activity were studied. The particle sizes of bare liposomes were in nanometer range. The gamma-oryzanol-loaded liposomes in formulations of PC/CHAPS and PC/NaTC liposomes were smaller than PC/Chol liposomes. The incorporation efficiency of 10% gamma-oryzanol-loaded PC/Chol liposomes was less than gamma-oryzanol-loaded PC/CHAPS liposomes and PC/NaTC liposomes allowing higher in vitro release rate due to higher free gamma-oryzanol in buffer solution. The antioxidant activity of gamma-oryzanol-loaded liposomes was not different from pure gamma-oryzanol. Both gamma-oryzanol-loaded PC/CHAPS liposomes and PC/NaTC liposomes were showed to enhance the antioxidant activity in NHF cells. gamma-oryzanol-loaded PC/Chol liposomes demonstrated the lowest cytotoxicity in NHF cells. It was conceivably concluded that liposomes prepared in this study are suitable for gamma-oryzanol incorporation without loss of antioxidant activity.
Viriyaroj
Amornrat
A
Faculty of Pharmacy, Srinakarinwirot University, Nakhon Nayok, Thailand.
Ngawhirunpat
Tanasait
T
Sukma
Monrudee
M
Akkaramongkolporn
Prasert
P
Ruktanonchai
Uracha
U
Opanasopit
Praneet
P
D000287:Administration, Topical; D000975:Antioxidants / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D001682:Biological Availability; D001713:Biphenyl Compounds / Q000737:chemistry; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002784:Cholesterol / Q000737:chemistry; D002793:Cholic Acids / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry* / Q000494:pharmacology; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D010316:Particle Size; D010666:Phenylpropionates / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D010713:Phosphatidylcholines / Q000737:chemistry; D010851:Picrates / Q000737:chemistry; D013656:Taurocholic Acid / Q000737:chemistry; D053835:Unilamellar Liposomes / Q000737:chemistry* / Q000494:pharmacology
D000975:Antioxidants; D001713:Biphenyl Compounds; D002793:Cholic Acids; D004337:Drug Carriers; D016166:Free Radical Scavengers; D010666:Phenylpropionates; D010713:Phosphatidylcholines; D010851:Picrates; D053835:Unilamellar Liposomes; D013656:Taurocholic Acid; D002784:Cholesterol; D006861:Hydrogen Peroxide; C004931:1,1-diphenyl-2-picrylhydrazyl; C028213:3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate; C013172:gamma-oryzanol